

	1
	DCT2
1.	3
2.	4
3.	4
	DCT4
DCT	7
1.	7
2.	/8
3.	9
4.	10
5.	11
6.	12
7.	/ eCOA.....	14
8.	14
9.	16
	17
1.	DCT	

5.	21
	21

/

Decentralized Clinical Trials DCT

/

DCT

Digital health technologies DHT

DHT

DCT

DCT

DCT

Good Clinical Practice

GCP

International

Council for Harmonisation of Technical Requirements for
Pharmaceuticals for Human Use, ICH

DCT

DCT “

” Fit for Purpose DCT

DCT

DCT

DCT

/

DCT DHT

DCT

/ DCT /
DCT

DCT

DCT

DCT

DCT

1.2

electronic

Clinical Outcome Assessment eCOA

DCT /DHT

DCT/DHT

DTP

DHT

6.1

DHT

DHT

DHT

DHT

6.2

DHT

DHT

Dose Limiting Toxicity

DLT

DLT/

Maximal Tolerable Dose MTD

DCT

DHT

APP

DCT

/

DCT

DHT

Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled Trial. *Drug Saf* 44, 223–233 (2021).

13. FDA, Discussion Document for Patient-Focused Drug Development Public Workshop on Guidance 3: SELECT, DEVELOP OR MODIFY FIT-FOR-PURPOSE CLINICAL OUTCOME ASSESSMENTS, October, 2018

14. .

15. Thorpe, K.; Fettiplace, J.; Gorey, C.; Kang, E. G.; Madden, K.; Bhat, S.; Zhang, S.; McLaughlin, M. M..Decentralized Clinical Trial (Dct) Design with the Potential to Improve Patient Recruitment and Retention in Glisten: A Phase 3 Study of Limerixibat for Cholestatic Pruritus in Patients with Primary Biliary Cholangitis (Pbc). *Hepatology* ; 76(Supplement 1):S1479, 2022.